Introduction
The ketogenic diet (KD) is a high-fat, low-carbohydrate, and adequate-protein diet. It is an established, effective non-pharmacological treatment that has been used as an alternative in the management of refractory epilepsy since the early 1920s. [1] [2] [3] [4] [5] [6] [7] [8] The KD is now considered a safe and effective optional therapy not only for children but also for adults with intractable epilepsy. 9, 10 Interest in the diet has been increasing despite the introduction of a number of new antiepileptic drugs. Although large series of patients have been reported, until recently there were few controlled-trial data. 1, 3, 9, [11] [12] [13] A recent randomized controlled trial supports its use in children with treatment-intractable epilepsy. 7 After three months, 28 patients (38%) of the diet group had a greater than 50% seizure reduction compared with four (6%) controls, and five children (7%) in the diet group had a greater than 90% seizure reduction compared with no controls. 7 A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy has shown that both diets are comparable in efficacy and tolerability. Clearly, these two ways of formulating the diet have their place in the treatment of childhood epilepsy. 8 It has been suggested that the diet might be beneficial for seizure control in specific epileptic syndromes. [9] [10] [11] [12] [14] [15] [16] [17] The KD is effective in all types of epileptic seizures. [9] [10] [11] [12] [14] [15] [16] A wide range of hypotheses has been proposed to explain the efficacy of the KD. [18] [19] [20] Different clinical studies and animal experiments have been conducted in an effort to elucidate the mechanisms of the KD. 19, 20 One hypothesis is that ketone bodies have anticonvulsant activity similar to antiepileptic drugs. In an experimental animal study, ketone bodies increased the inhibition mechanisms in the hippocampal dentate gyrus. [18] [19] [20] Acetone may also exert an anticonvulsant effect. A brain ketone may be elevated by the KD. 10, [18] [19] [20] Alternative mechanisms for the action of the KD are the direct action of aceto acetate or b-hydroxy-butyrate, and changes in the source or utilization of energy within the brain, an increase in brain gamma-aminobutyric acid, and the potential Purpose: The ketogenic diet (KD) has been used as an alternative to antiepileptic drugs (AEDs) for patients with refractory epilepsy. Lennox-Gastaut syndrome (LGS) belongs to the group of epileptic encephalopathies that often prove refractory to AED treatment.
In this prospective study we assess the efficacy and tolerability of the KD in patients with LGS. Methods: Between March 1, 1990 and April 1, 2013, 61 patients who met diagnostic criteria of LGS were seen at our department. Twenty of them were placed on the KD and followed for a minimum of 16 months. Results: The children had previously received a mean of 6.5 different AEDs and were on a mean of 2.5 AEDs when the diet was started. Eighteen months after initiating the diet, fifteen of the initial patients (75%) remained on the diet; three patients (15%) were seizure free, three (15%) had a 75-99% decrease in seizures, two (10%) had a 50-74% decrease in seizures, and the remaining seven children (35%) had a <50% decrease in seizures. Three seizure-free patients were tapered off the diet after remaining seizure free. In the three patients who had a 75-99% decrease in seizures AEDs were reduced. Conclusion: The KD is an effective and well-tolerated treatment option for patients with LGS, not only for those with cryptogenic, but also for those with structural LGS. The diet should be considered early in the course of this syndrome.
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effects of changes in water and electrolytes have also been indicated as antiepileptic mediators. 19, 20 Recent reports of series of patients after one year on the diet show an overall efficacy ranging from 15 to 50% of patients having a >50% reduction in seizures. [2] [3] [4] [5] [6] [7] [8] Lennox-Gastaut syndrome (LGS) is now classified among the epileptic encephalopathies, 21, 22 with a high seizure frequency and refractoriness to antiepileptic drugs (AEDs).
LGS is characterized by a triad of symptoms: (1) epileptic seizures: axial tonic, atonic, and atypical absences, (2) EEG abnormalities: bursts of diffuse slow spikes and waves during wakefulness and bursts of diffuse fast rhythmic waves and slow polyspikes and generalized fast rhythms at about 10 Hz during sleep, and (3) a slowing of intellectual growth and associated personality disorders. 23 The etiological spectrum is broad, including structural, congenital or acquired, metabolic, infectious, and other causes. Cryptogenic cases of LGS have also been recognized. 23 LGS may evolve from West syndrome or from unspecified epilepsies, or it may represent the first seizure manifestation. Approximately one-third of patients with a structural cause have a history of spasms occurring in infancy and early childhood. Seizures begin before the age of 8 years, with a peak between 3 and 5 years. Onset after the age of 10 years is rare.
In this prospective study, we evaluate the efficacy and tolerability of the KD in patients who met the diagnostic criteria of LGS.
Materials and methods
Between March 1, 1990 and August 31, 2013, 61 patients who met the diagnostic criteria of LGS were seen at our center. Twelve patients (19.6%) had cryptogenic and the remaining 49 patients (80.4%) had structural LGS. Twenty of these 61 patients were placed on the KD using the Hopkins protocol 1 and followed for a minimum period of 16 months. Thirty-five patients with refractory seizures were not offered the KD as they came from families who were considered not to be prepared to follow the diet, from families with a low socioeconomic level, and/or were adolescents. Six patients with LGS responded well to AEDs.
Frequency of the seizures was registered using daily seizure calendars kept by the parents. Electroencephalograms during wakefulness and sleep were performed at least three months before starting, while on, and after discontinuing the KD. All patients underwent intermittent photic stimulation (IPS). Baseline blood tests and lipid profiles were also obtained. Serum bicarbonate levels were measured in all patients.
Children started fasting in the hospital for 36-48 h and were then gradually initiated on the classic KD (Johns Hopkins protocol). Children were begun on a 4:1 ratio (fat:protein plus carbohydrate) and stayed in hospital for another four days for close monitoring. During this period parents were taught about the diet. They were asked to keep the child on the diet for at least two months to regulate the diet for optimal tolerance and seizure control. The ratio of the diet was progressively modified as needed to maintain 80-160 mg/dl urinary ketosis, and to avoid weight loss. Adverse events and reasons for diet discontinuation were recorded, as were changes in medication.
Results
Sixty-one children with a diagnosis of LGS were followed for 2-20 years. Of these children, 20 (13 boys and 7 girls) were placed on the KD as add-on to the use of one to three AEDs. Ages at initiation of the KD were between 6 and 12 years (mean 7.5 years).
All patients had more than one type of seizure before starting the diet: Three patients had two types, 14 had three types, and two had more than three types of seizures. Patients with tonic and absence seizures had an average of 93 and 86 episodes a month, respectively. Patients with atonic seizures had an average of 51, those with generalized tonic-clonic seizures had an average of 35, those with myoclonias had an average of 30, those with epileptic spasms had an average of 20, and those with focal seizures had an average of 26 episodes a month.
The children had previously received a mean of 6.5 different AEDs and were on a mean of 3.5 AEDs when the diet was begun.
Six cases of 20 were cryptogenic. Fourteen patients had structural lesions, five of them had an acquired etiology, four Table 1 The electroclinical features, treatment, and evolution of the patients before starting the KD.
Patients
Age at onset (years) had malformations of cortical development, two had tuberous sclerosis, two had down syndrome, and the remaining patient had vascular disease. Considering efficacy of the diet, no differences were found according to etiology. Table 1 shows the electroclinical features, treatment, and evolution of the patients before diet initiation and in Table 2 while on the KD.
Duration on the diet
One of the 15 original children stayed on the diet for 18 months, three children remained on the diet for 2 years, six children for 3 years, one for 5 years, three children remained on the diet for 6 years, and one child for 8 years.
Efficacy of the diet
Eighteen months after initiating the diet, fifteen of the initial patients (75.5%) remained on the diet. Three patients (15%) were seizure free, three children (15%) had a 75-99% decrease in seizures, two patients (10%) had a 50-74% decrease in seizures, and the remaining seven children (35%) had a less than 50% seizure reduction. All three patients that became seizure free had cryptogenic LGS; the remaining patients who continued on the diet had structural LGS, except one cryptogenic patient with a 75-99% and another with a 50-74% decrease in seizures, respectively. Thus, 18 months after starting the diet, eight patients (40%) had achieved a more than 50% decrease of seizures. Two patients have been off the diet for several years and remain seizure free, one of whom does not receive any AEDs. Three patients have sporadic seizures, but AEDs were reduced to one. Three patients have monthly seizures, four have weekly seizures, and the remaining patients have daily seizures. In our series of patients, the KD was effective mainly in tonic, atonic, myoclonic-atonic seizures and epileptic spasms. We also observed that the diet worked in atypical absences, generalized tonic-clonic seizures, and less frequently in focal seizures. One patient who had a less than 50% decrease in seizures, combination with vagus nerve stimulation (VNS) was used, significantly improving seizure control.
Reasons for discontinuing the diet, tolerability, and adverse events
Five of the 20 children (25%) who initiated the diet discontinued within the first year. In three, the reason given for discontinuing the diet was lack of effectiveness. Two of these children discontinued after between 1 and 2 months and one discontinued 3 months after starting the diet. Table 2 The electroclinical features, treatment, and evolution of the patients while on the KD and at the last follow-up.
Patients
Age at initiation (years) In two children persistent and severe vomiting, added to hypoglycemia in one, was the reason for discontinuing the diet one month after the initiation. Fifteen patients who remained on the diet for more than one year did not develop severe complications, such as high levels of uric acid, kidney stones, severe acidosis, lethargy, or hypoglycemia.
Electroencephalographic changes
In all patients who followed the KD with good response, EEG recordings of at least 3 months before starting the KD showed very frequent symmetric or asymmetric bilateral slow spikes and waves, fast diffuse paroxysms, diffuse spike-and-polyspike paroxysms, and focal and multifocal spikes. Eighteen months after initiating the diet, the EEG abnormalities had improved in all of them. The EEG recording was normal in two of three patients who became seizure free. In the remaining seizure-free patient, and in three patients who achieved a 75-99% seizure reduction, the EEG recording showed infrequent generalized spikes and waves and polyspikes and waves, and sporadic diffuse fast paroxysms. In both patients who achieved a 50-74% seizure decrease, EEG abnormalities during sleep improved between 50% and 70%. In the remaining seven patients with a seizure reduction of less than 50%, the EEG abnormalities during sleep improved between 25% and 50%. The changes of abnormalities were determined according to the quantity of paroxysmal discharges on the sleep EEG recording.
The EEG abnormalities remained unchanged in the patients in whom the diet proved to be ineffective and in the patients who did not tolerate the diet.
Decreasing and discontinuing medications
Medications were decreased and discontinued non-systematically with the aim of the patient becoming medication free.
Two of three patients who became seizure free had a cryptogenic or unknown etiology. They do not receive any AEDs and have a normal IQ and EEG recording after 3.5 and 9 years of follow-up, respectively. The remaining seizure-free patient is on valproic acid (800 mg per day). The neuropsychological profile returned to baseline and the EEG shows sporadic generalized polyspikes and waves after 2 years of follow-up.
Discussion
Our experience with the KD in 20 children with LGS shows an overall good response in terms of seizure frequency and tolerability, not only in the cryptogenic but also in the structural group.
The ketogenic diet has been recommended by several authors for children with severe epilepsy, amongst which LGS. 10, 14, 15 Freeman et al. 24 have studied the effectiveness of the KD versus an inactivated KD with glucose intake in a series of 20 LGS subjects. Seizure frequency decreased significantly and rapidly in the KD group.
Interictal epileptiform abnormalities improved in most of our patients who had a seizure reduction of more than 75%. Similar findings have been reported in the literature. 25, 26 The KD has been successfully used in children with a variety of seizure types and epileptic syndromes, especially epileptic encephalopathies including LGS, 9, 10, 14, 15, [27] [28] [29] [30] West syndrome 11, 12, 29, 30 epilepsy with myoclonic atonic seizures, 31, 32 Dravet syndrome, 27, 28 Landau-Kleffner syndrome, 33 Tassinari syndrome, 29 and FIRES. 29 Recently, Mullen et al. 34 have shown that 5% of children with epilepsy with myoclonic atonic seizures have glucose transporter 1 deficiency with mutations of the SLC2A1 gene. In this entity, the KD should be introduced early in the treatment of the disorder with potential beneficial effects for cognition as well as seizure control. In patients with cryptogenic
LGS, glucose transporter 1 deficiency should be ruled out. As in our studies on the treatment of patients with Dravet syndrome (DS) 27, 28 and epilepsy with myoclonic and atonic seizures 31 with the KD, no differences were found in the effect of the diet on the seizure types. It is interesting to note that a significant number of patients in our previous studies 25 as well as in this study who responded well to KD additionally received topiramate. This association may increase the risk of kidney stones, but may also improve seizure control. 35 In this study, one patient with a less than 50% seizure reduction, VNS was implanted with a good response. This combined therapy between KD and VNS was considered a rational polytherapy. The combined use of the diet and VNS appeared synergistic. 36 We believe that more precise definitions of epileptic syndromes may lead to the possibility of giving a clear prognosis in each particular case. 9, 10, 14, 16, 29 Families that are able to make the effort that treatments such as the KD require in children have to be carefully selected so as to reduce the number of failures. Risk families are those in whom the parents are considered not to be able to strictly follow the diet for different reasons, such as having numerous children or having psychological problems. In developing countries, caregivers may not have the financial means to confront the extra cost posed by the diet.
Conclusion
The KD is a promising therapy for LGS, with over half of the children showing a >50% reduction in seizures, and 20% achieving seizure freedom. It should be considered early in the course of the syndrome, and not as a last resort. The patients that responded well to the diet did not further mentally deteriorate. The youngest child on the KD in our series of patients with LGS was 5 years old.
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